News and Updates about the regulations in Drugs and Pharma
The All India Institute of Medical Sciences (AIIMS), located in New Delhi, has entered into a Memorandum of Understanding (MoU) with Wipro GE Healthcare Pvt Ltd, a global leader in healthcare technology, to launch an AI Health Innovations Hub. This […]
Beacon Biosignals, a global frontrunner in at-home EEG and AI-enhanced brain health analysis, showcased two scientific posters at the American Epilepsy Society (AES) annual conference. These presentations spotlight innovative research stemming from collaborations with Longboard Pharmaceuticals and UCB, aimed at
Global Commitment to Transforming Patient Lives: FDA to Review Ascendis’ Application for TransCon hGH Ascendis Pharma A/S, a worldwide pharmaceutical leader harnessing the transformative potential of its TransCon technology, strives to emerge as a foremost and cohesive biopharmaceutical entity dedicated
A significant research project indicates a correlation between prolonged exposure to air pollution and elevated risks of venous blood clots. These clots, if not treated, may obstruct blood circulation, causing severe health issues, potentially even fatalities. The study, supported by
NIH-Funded Research Connects Long-Term Air Pollution Exposure to Venous Blood Clots Read More »
Roche has announced that its latest cobas 6800/8800 systems 2.0 have obtained CE certification. This revision significantly boosts operational efficiency in lab settings by optimizing resources, minimizing downtime, consolidating testing options, and increasing capacity. These advancements aim to deliver a
Roche Unveils CE Certified Enhanced Molecular cobas 6800/8800 Systems Read More »
Vir Biotechnology, Inc, an advanced-stage biopharmaceutical firm dedicated to utilizing the immune system for medical breakthroughs in severe infectious diseases and cancer, has announced that the US Food and Drug Administration has granted breakthrough therapy designation to tobevibart and elebsiran,
Bayer has begun a phase I clinical trial for BAY3498264, an investigative oral selective inhibitor targeting Son of Sevenless Homologue 1 (SOS1). The open-label, first-in-human study (NCT06659341) will assess the safety, tolerability, and initial effectiveness of BAY3498264 in combination therapies
Bayer Begins Phase I Clinical Trial for SOS1 Inhibitor in KRAS-Mutated Tumors Read More »
BeiGene, Ltd., soon to be rebranded as BeOne Medicines Ltd., has disclosed a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CSPC) for SYH2039. This innovative methionine adenosyltransferase 2A (MAT2A) inhibitor is in exploration for potential uses
Pfizer Inc., in collaboration with Alliance Foundation Trials, LLC (AFT), has shared outcomes from the phase 3 PATINA trial. The investigation highlighted that incorporating Ibrance (palbociclib) into the existing standard first-line maintenance treatment (post induction chemotherapy) significantly boosted progression-free survival
Roche has announced that the European Medicines Agency (EMA) has given the green light to Vabysmo (faricimab) 6.0 mg prefilled syringe for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following